

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2022**

**Commission File Number: 001-39545**

---

**Orphazyme A/S**  
(Translation of registrant's name into English)

---

**Ole Maaløes Vej 3, DK-2200  
Copenhagen N  
Denmark**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**EXHIBIT LIST**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
99.1	<a href="#">Company announcement dated June 20, 2022</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Orphazyme A/S**

Date: June 21, 2022

By: /s/ Anders Vadsholt

Name Anders Vadsholt

Title: Chief Financial Officer

**Company announcement**

No. 32/2022

**Orphazyme A/S**  
Ole Maaløes Vej 3  
DK-2200 Copenhagen N[www.orphazyme.com](http://www.orphazyme.com)

Company Registration No. 32266355

**Updated notice to holders of ADSs regarding termination of Deposit Agreement**

NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”)  
EVIDENCED BY  
AMERICAN DEPOSITARY RECEIPTS (“ADRs”)  
REPRESENTING DEPOSITED COMMON SHARES OF:  
ORPHAZYME A/S ONE ADS REPRESENTS ONE COMMON SHARE  
CUSIP: 687305102 AND UNDERLYING ISIN: DK0060910917

**Copenhagen, Denmark, June 20, 2022** – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) representing deposited common shares of the Company regarding termination of the Deposit Agreement (the “Deposit Agreement”) dated September 28, 2020 among the Company, The Bank of New York Mellon, as depositary (the “the Depositary”), and Owners and ADR Holders (“ADR Holders”).

On April 5, 2022, ADR Holders were notified by the Depositary that the Depositary will terminate the Deposit Agreement effective at 5:00 PM (Eastern Time) on July 6, 2022.

Under the terms of the Deposit Agreement, ADR Holders have until at least July 11, 2022, to surrender their Orphazyme ADRs for delivery of the underlying shares. If ADR Holders surrender ADRs for delivery of the underlying shares, ADR Holders must pay a cable fee of \$17.50, a cancellation fee of up to \$0.05 per ADR surrendered and any applicable U.S. or local taxes or governmental charges. Payment should be made payable to the Depositary.

Subsequent to July 11, 2022, under the terms of the Deposit Agreement, the Depositary may attempt to sell the underlying shares. If the Depositary has sold such shares, ADR Holders must surrender their ADRs to obtain payment of the sale proceeds, net of the expenses of sale, any applicable U.S. or local taxes or government charges and a cancellation fee of up to \$0.05 per ADR.

In order to convert ADSs to common shares of the Company, ADR Holders should instruct their brokers to surrender ADSs to The Bank of New York Mellon (DTC No. 2504). In connection with this surrender, brokers should include ongoing common share delivery instructions in the comments field within DTC, including information such as the name and BIC of the appropriate local bank/broker and/or appropriate delivery code, beneficiary name and account number. U.S. brokers holding ADSs on behalf of their clients, can reach out to [DRSettlements@BNYMellon.com](mailto:DRSettlements@BNYMellon.com) for questions regarding the conversion and settlement process.

**For additional information, please contact**

**Orphazyme A/S**

Anders Vadsholt, Chief Executive Officer and Chief Financial Officer

+45 2898 9055